Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Abstract: Embodiments of this application provide a coil alignment method and a charging system.

Abstract: A charging/discharging circuit and an electronic device. A first end of a first branch is connected to a voltage supply end, a second end thereof is connected to a first battery, and a voltage provided by the voltage supply end charges the first battery through the first branch; a first end of a second branch is connected to the voltage supply end, a second end thereof is connected to a second battery, and the voltage provided by the voltage supply end charges the second battery through the second branch; the second branch includes a first control circuit that is configured to adjust impedance of the second branch; and a processing module is configured to obtain a first current of the first branch and a second current of the second branch, and indicate, based on the first and second currents, the first control circuit to adjust impedance of the second branch.

Abstract: Provided are a preparation method for a CTL cell and an application thereof. The preparation method comprises the following steps of: inducing a CTL cell by using a tumor antigen PAP-GM-CSF sensitized DC cell; and knocking out a PD-1 gene of the CTL cell to obtain a PD-1 knock-out CTL cell. The CTL cell obtained by the preparation method can be used for preparing drugs for treatment of prostate cancer, especially for treating PAP-positive prostate cancer. The CTL cell does not cause CTL cell failure and anergy due to the tumor-expressed PD-L1 after being transfused into the body, thereby producing efficient specific cytotoxic effect on a tumor cell and improving the curative effect and reducing the side effect.

Abstract: A power supply circuit of a terminal device includes a voltage boost circuit, a battery chip, and a controller. The battery chip is configured to provide an output voltage of a battery for a load. An input end of the voltage boost circuit is connected to a positive electrode of the battery, and an output end of the voltage boost circuit is connected to the load. The output voltage of the battery is boosted when the temperature is relatively low or the output voltage of the battery is relatively low. In addition, when a relatively high pulse current occurs on the terminal and the output voltage of the voltage boost circuit is stepped down, both the battery chip and the voltage boost circuit is controlled to supply power to the load.

Abstract: A wireless charging device (20) and a to-be-charged device (10) are provided, to support two or more wireless charging technologies, so as to optimize a circuit design and improve power transmission efficiency. The to-be-charged device (10) includes: a first receiving coil, configured to receive an electromagnetic signal based on a first wireless charging technology, and convert the electromagnetic signal into an alternating current signal; and a second receiving coil, configured to receive an electromagnetic signal based on a second wireless charging technology, and convert the electromagnetic signal into an alternating current signal, where the first wireless charging technology and the second wireless charging technology support different resonance frequency ranges.

Abstract: An electronic device may collect statistics on a quantity of recharging times of the battery in at least one single charging process, and/or obtain a temperature of the battery in recharging. Then, the electronic device may lower a full charge threshold and a recharge threshold based on the quantity of recharging times and/or the temperature, and control recharging by using a lowered full charge threshold and a lowered recharge threshold.

Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.

Abstract: The present disclosure relates to methods of treating or preventing graft-versus-host disease (GVHD) comprising administering to the subject a pharmaceutically effective amount of a compound disclosed herein. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.

Abstract: Provided is an application of an amino acid as a vehicle for delivery of a nucleic acid into the nervous system. By local injection, preferably, combined with means of stereotactic injection, immunofluorescence staining, confocal microscopy, etc., the single-stranded oligonucleotides are efficiently delivered into brain cells, and the plasmid vectors are also delivered into astrocytes in mouse brain.

Abstract: The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or degraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

Abstract: A wireless charging device (20) and a to-be-charged device (10) are provided, to support two or more wireless charging technologies, so as to optimize a circuit design and improve power transmission efficiency. The to-be-charged device (10) includes: a first receiving coil, configured to receive an electromagnetic signal based on a first wireless charging technology, and convert the electromagnetic signal into an alternating current signal; and a second receiving coil, configured to receive an electromagnetic signal based on a second wireless charging technology, and convert the electromagnetic signal into an alternating current signal, where the first wireless charging technology and the second wireless charging technology support different resonance frequency ranges.

Abstract: An image data acquisition device includes a camera, an elevating system, and a control processor. The camera covers a photographing scene, and is configured to capture images of a plurality of objects in the photographing scene. The elevating system is connected to the camera and moves the plurality of objects in and out of the photographing scene, and moves the plurality of objects in the photographing scene to meet a preset placement condition. The control processor is configured to control the elevating system to move the plurality of objects in the photographing scene in a preset order to meet the preset placement condition, to control the camera to capture an image of the plurality of objects meeting the preset placement condition, and to label the image of the plurality of objects through image annotation.

Abstract: A battery module includes a battery cell, and the battery cell includes a battery cell body, a first tab, a second tab, and a third tab. The first tab, the second tab, and the third tab are separately electrically connected to the battery cell body. The first tab and the third tab have a first polarity, and the second tab has a second polarity. Working together, the second tab and the first tab are capable of inputting a voltage and a current to the battery cell body or capable of outputting a voltage and a current from the battery cell body. Working together, the second tab and the third tab are capable of inputting a voltage and a current to the battery cell body or capable of outputting a voltage and a current from the battery cell body. The first polarity is different from the second polarity.

Abstract: The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

Abstract: A charging apparatus includes a sampling module, a control module, a clamping module, and a switched capacitor module. The sampling module is configured to connect to a battery, collect current status information of the battery, and provide collected status information for the control module, the control module is configured to adjust output energy of the clamping module based on the status information, and provide a drive signal for the switched capacitor module, the clamping module is configured to connect to a power supply, receive power supply energy provided by the power supply, process the power supply energy into output energy, and provide the output energy for the switched capacitor module, and the switched capacitor module is configured to provide charging energy for the battery based on the drive signal provided by the control module and the output energy provided by the clamping module.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.

Abstract: A power supply circuit of a terminal device includes a voltage boost circuit, a battery chip, and a controller. The battery chip is configured to provide an output voltage of a battery for a load. An input end of the voltage boost circuit is connected to a positive electrode of the battery, and an output end of the voltage boost circuit is connected to the load. The output voltage of the battery is boosted when the temperature is relatively low or the output voltage of the battery is relatively low. In addition, when a relatively high pulse current occurs on the terminal and the output voltage of the voltage boost circuit is stepped down, both the battery chip and the voltage boost circuit is controlled to supply power to the load.

Abstract: A charging apparatus includes a sampling module, a control module, a clamping module, and a switched capacitor module. The sampling module is configured to connect to a battery, collect current status information of the battery, and provide collected status information for the control module; the control module is configured to adjust output energy of the clamping module based on the status information, and provide a drive signal for the switched capacitor module, the clamping module is configured to connect to a power supply, receive power supply energy provided by the power supply, process the power supply energy into output energy, and provide the output energy for the switched capacitor module, and the switched capacitor module is configured to provide charging energy for the battery based on the drive signal provided by the control module and the output energy provided by the clamping module.

Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.